𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of refractory myasthenia: “Rebooting” with high-dose cyclophosphamide

✍ Scribed by Daniel B. Drachman; Richard J. Jones; Robert A. Brodsky

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
81 KB
Volume
53
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of refractory, systemic lupus
Treatment of refractory, systemic lupus erythematosus–associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide
✍ Barbara A. Roach; Gordon J. Hutchinson 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views

lupus patient with severe, treatment-resistant thrombocytopenia, which was successfully treated with lowdose IV bolus cyclophosphamide and prednisone after several other treatments had failed.

Activity of high-dose cyclophosphamide i
Activity of high-dose cyclophosphamide in the treatment of childhood malignant gliomas
✍ McCowage, Geoffrey B.; Friedman, Henry S.; Moghrabi, Albert; Kerby, Tracy; Ferre 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 2 views

Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokines (GM-CSF or G-CSF). Cyclophosphamide was gi

High-dose cyclophosphamide in the treatm
High-dose cyclophosphamide in the treatment of severe aplastic anemia in children
✍ José Carlos Jaime-Pérez; Oscar González-Llano; David Gómez-Almaguer 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 2 views

FL 33612 to permit rapid consideration for publication. ## Mutations in the Factor XI Gene To the Editor: Mutations in the factor XI gene are responsible for a variable bleeding phenotype which correlates poorly with levels of circulating FXI product. We read with interest and concern an article